A phase 2 study of RP2 for the treatment of patients with liver metastases from a range of solid tumor types
Latest Information Update: 13 Dec 2022
At a glance
- Drugs RP 2 (Primary)
- Indications Liver metastases
- Focus Therapeutic Use
- 07 Dec 2022 According to a Replimune media release, this study will initiate in the first half of 2023.
- 09 Jun 2021 New trial record
- 03 Jun 2021 According to a Replimune media release, the company is planning to initiate this study in the first half of 2022. Details of the clinical trial design will be announced at a later time.